Thus, we have conducted a meta-analysis of randomized controlled trials comparing the efficacy and risk of all the reported adverse events in melanoma between BRAF inhibition alone and combined BRAF and MEK inhibition. This evidence concerns the gene MAP2K7 and melanoma.